🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

GMED GMED

Company Profile ↓
$80.54
+50.18% 1Y
P/E20.55
52W High$96.82
52W Low$52.83
EPS (TTM)$3.92

Company Overview

GMED (GMED) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 16.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.7% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 18.3%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.94B (+16.7% YoY); net profit $537.87M.
  • Trailing 12 Months Year-on-year growth — revenue +16.7%, earnings +422.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.7%, profit CAGR 16.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.74%
1 Year:16.65%

Compounded Profit Growth

5 Years:16.50%
1 Year:422.28%

Stock Price Performance

1 Year:+50.18%
6 Months:-7.90%
3 Months:-10.54%
1 Month:+2.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 63% of range
$52.83 $96.82
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)53.05 · Neutral
Price Performance
1M+2.17%
3M-10.54%
6M-7.90%
1Y+50.18%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.7% over 5 years.
  • Profit CAGR of 16.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.55
Industry PE
-
Forward P/E est.
10.28
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
16.74%
Profit 5Y
16.50%
Revenue (YoY)
16.65%
Earnings (YoY)
422.28%

Profitability & Returns

ROCE
9.99%
ROE
11.76%
ROA
10.14%
Profit Margin
18.30%
Op Margin
16.33%
Gross Margin
34.72%
EPS (Latest Qtr)
$0.90
EPS (TTM)
$3.92

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$5.44B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.73%
Chg in Prom Hold
-
FII / Inst Holding
102.01%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$2.94B
EBITDA
-
Free Cash Flow
$588.77M
Operating Cash Flow
$753.45M
Shares Outstanding
-
Gross Margin
34.72%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue --------155.81M152.39M151.74M176.03M174.41M173.38M169.24M195.94M182.95M194.54M196.22M211.67M190.58M148.92M216.10M233.44M227.34M251.02M229.72M230.55M263.65M254.15M276.69M291.62M383.64M606.67M629.69M625.71M598.12M745.34M769.05M759.85M
Gross Profit 99.59M101.12M104.06M107.65M107.75M104.76M104.20M112.59M120.21M115.19M114.95M135.18M136.44M135.75M131.39M149.98M141.11M150.55M150.83M162.91M141.71M98.28M159.00M172.59M172.32M187.17M171.17M171.38M195.18M188.65M205.86M215.14M248.25M365.18M369.65M-----
Operating Income 38.52M37.03M40.67M-42.85M37.92M37.65M-40.31M37.37M35.80M-45.63M42.14M38.30M-37.08M42.87M42.06M-28.45M-25.56M50.01M-54.55M45.88M53.33M46.45M67.78M59.70M56.40M66.21M404.00K8.00M49.62M48.10M97.00M76.11M137.36M150.39M
Net Income 24.65M24.05M26.48M37.60M28.01M25.81M26.23M24.30M28.71M28.67M25.59M24.38M39.54M44.98M35.21M36.75M33.21M38.16M38.31M45.53M25.95M-20.84M44.22M52.96M45.33M41.55M47.21M38.08M54.59M47.43M49.13M57.71M998.00K-7.12M31.76M51.84M75.46M202.85M118.97M124.30M
Diluted EPS 0.260.250.280.390.290.270.270.250.300.290.260.250.390.440.350.360.330.380.380.440.25-0.210.440.520.440.400.450.370.530.470.480.570.01-0.050.230.380.541.490.880.90
R&D Expense 8.66M9.08M9.25M-10.03M10.59M10.27M-10.67M10.71M10.89M-12.69M13.52M15.53M-14.32M15.75M14.51M-15.40M39.45M14.42M-14.92M15.55M15.85M17.41M17.39M18.70M21.08M21.35M29.33M57.27M37.70M35.38M33.06M39.95M38.07M36.51M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 288.19M331.48M385.99M434.46M474.37M544.75M563.99M635.98M712.97M785.37M789.04M958.10M1.02B1.57B2.52B2.94B
Gross Profit 234.37M262.68M310.80M334.12M363.60M412.42M429.29M485.52M553.56M605.39M571.58M718.88M759.12M1.02B--
Operating Income 87.69M97.36M114.79M101.67M138.36M172.22M154.14M161.84M169.32M171.99M111.43M171.95M227.95M133.14M165.99M479.82M
Net Income 54.46M60.78M73.83M68.61M92.48M112.78M104.34M107.35M156.47M155.21M102.28M149.19M190.17M122.87M102.98M537.87M
Diluted EPS 0.600.670.800.730.971.171.081.101.541.521.011.441.851.070.753.92
R&D Expense 21.31M23.46M27.93M26.87M31.17M36.31M44.53M43.68M55.50M60.07M84.52M97.35M73.02M124.01M163.75M147.25M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --329.39M447.13M566.30M703.55M834.10M927.64M1.08B---1.30B---1.53B---1.68B---1.96B---2.08B5.09B5.25B5.30B
Total Equity 167.75M228.19M282.48M386.50M472.36M585.45M715.32M832.08M967.78M1.03B1.10B1.14B1.19B1.24B1.29B1.34B1.40B1.36B1.34B1.42B1.51B1.56B1.64B1.72B1.74B1.79B1.70B1.76B1.85B4.00B4.18B4.57B
Cash & Equivalents 50.65M111.70M142.67M212.40M89.96M82.27M57.65M66.95M118.82M---139.65M---195.47M-------------784.44M526.16M
Total Liabilities --46.91M60.63M93.94M118.09M118.78M95.56M110.72M---115.15M---129.62M---173.19M---215.88M---229.75M1.09B1.07B729.51M
Current Liabilities --29.27M39.51M67.94M89.41M82.69M79.89M93.07M---96.12M---111.40M---120.79M---140.16M---159.20M392.35M855.91M498.50M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 71.29M76.41M76.52M93.47M79.17M124.01M147.82M159.06M181.64M171.97M198.79M276.27M178.47M243.50M520.64M753.45M
Investing Cash Flow -12.00M-29.99M-30.71M-227.15M-100.00M-153.05M-162.74M-111.28M-193.03M-140.28M-117.32M-375.94M-110.36M302.97M-176.05M-355.01M
Financing Cash Flow 1.77M-14.73M24.02M11.01M12.95M4.28M470.00K1.63M32.57M24.44M-38.66M54.15M-109.96M-231.82M-27.70M-679.16M
Capital Expenditure -12.30M-22.49M-24.68M-23.68M-24.75M-50.76M-40.91M-51.30M-59.70M-70.75M-63.66M-56.90M-74.05M-78.27M-115.43M-164.68M
Free Cash Flow 58.98M53.92M51.84M69.79M54.42M73.25M106.91M107.75M121.95M101.22M135.13M219.38M104.42M165.22M405.21M588.77M
Share Buybacks 010.02M00------104.67M-144.49M225.56M85.79M300.45M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 81.3%79.2%80.5%76.9%76.6%75.7%76.1%76.3%77.6%77.1%72.4%75.0%74.2%65.1%--
Operating Margin % 30.4%29.4%29.7%23.4%29.2%31.6%27.3%25.4%23.7%21.9%14.1%17.9%22.3%8.5%6.6%16.3%
Net Margin % 18.9%18.3%19.1%15.8%19.5%20.7%18.5%16.9%21.9%19.8%13.0%15.6%18.6%7.8%4.1%18.3%
ROE % 23.9%21.5%19.1%14.5%15.8%15.8%12.5%11.1%13.2%11.1%6.8%8.6%10.3%3.1%2.5%11.8%
ROCE % -32.4%28.2%20.4%22.5%22.9%18.2%16.4%14.1%12.1%7.1%9.5%11.9%2.8%3.8%10.0%

Shareholding Pattern

Insiders
0.73%
Institutions
102.01%
Public Float
102.76%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GMED

Google News Wed, 05 Aug 2026

Unlocking Q2 Potential of Globus Medical (GMED): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPQTdnNEwzVXRlSTFrU01JcGZJV0s4am9ldk92TXY2dWpIQmxrcDhLYW9YS01SUHpzNEozN3NOMjlrYUoxcXl6WTVzeDllMjBYRl9FUEdFc2lZVUFZcTFxU2tZTVZCWmpiWk5HT2MwRVVZaGRKNFUwUTNPd1VjdnpsUWstdGV1bVB3ZUFJdD…

Google News Mon, 03 Aug 2026

Globus Medical, Inc. (GMED) Stock Analysis: Unveiling a 31.90% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZOQU5QZUJtR2s3R3V3WF9FSGxwb1ZhX2tGLWVyZTVwUUREREF2UEpvNmdsX0NWWjBPekE4X2wyVm9UVEJOSUxaQkhXVkNKSmkwdVNQcnB2S29GcUd0Z25DcWF5NEljaGhHQ1B0N25Ka2RITF9KTFhZV1VuTTBYY1dqeU5vTEh3NUlsaD…

Google News ue, 04 Aug 2026

Globus Medical Inc (GMED) Stock Up 3.4% and Still Undervalued -- GF Score: 95/100 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPd3I2LUljaGR5R3VGblgzZXlZSndnb1hqeXQ2eU5kNEhicXg2dW94YjV3TlZad21BNThQLVI5a0o1UHJIdUlvdGF5V0stMms5cHFLNHRrTUZkV0Q2T0tSWENhcFFkTlFHOEozTjdzRW84RXpUOGxLb1RCMGV2bUlKQ3ZWWDVSZnY2Ti1oTj…

Google News hu, 30 Jul 2026

Globus Medical (GMED) Emerges as a Decent Value Stock with Strong Fundamentals - ChartMill

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQVzN0NG9HcWNzQkZzTUMzWHlmTUNyZFdYUlBkRjNnYXNFMG5ETE5BSlhxaGpQNV9leGRvZzFGZ0pIeEZXTU9mZHdidFMzRU0wSzMwcjh1dnB2SDlLX3h4QzdMd200dHRxVjhFOVMxeXQ3bVoyTXF2SDBhR0hBVGp1c1c3dlJOZGVONVhSMz…

Google News hu, 30 Jul 2026

Globus Medical (GMED) Stock Could Be Undervalued Following Q2 Earnings Date - Sahm

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUXlnVExKNXUyYTZTOGJWcy16NnpxQU8ySzJEZ0duSERuN2liRlluU1ZmVEU4dnZYWTBBR2d1OUVwWWR2QjFNM1Zpa0FvazY3TEtLOVlCZnNlM3kxVlFwZWozbmUzQ19JcGg1bU9QMUt0YndDSWZNYURXYTZHQnZXMEhrTHhVYUh3WGJaa0…

Google News Wed, 22 Jul 2026

Reasons to Retain Globus Medical Stock in Your Portfolio for Now - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOQkhnbjQ1MC1wWWFCcnYzUFVpNnZfRmJGQlZ3LXg5OXcxNXdDZ3RIbDNKUTVMRjJPOVJCTTZXWTIzY0xiSmF4TExjZmpqMExsQTdIdVJqamQ3ZUI3M0J1blVwV0F6ekpEczZZaHNvbTl6VTQzUUNkLWJsV3R2RTM3T3d6eXpTVnZUeUFDZF…

GMED — Frequently Asked Questions

What is the current share price of GMED?

As of 2026-08-05 17:25 PDT, GMED trades at $80.54 on NASDAQ/NYSE. Its 52-week range is $52.83 to $96.82.

What is the P/E ratio of GMED?

GMED trades at a trailing price-to-earnings (P/E) ratio of 20.55.

What is the return on equity (ROE) of GMED?

GMED has a return on equity (ROE) of 11.76%. Its return on capital employed (ROCE) is 9.99%.

Is GMED a good stock to buy?

This page provides a data-driven analysis of GMED, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space